Vimarsana
Biggest News Aggregation in the World

Page 16 - Toddler Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Toddler Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Toddler Development Today - Breaking & Trending Today

F. Hoffmann-La Roche Ltd: FDA approves Roche's Evrysdi for use in babies under two months with spinal muscular atrophy (SMA) - Vimarsana News

F. Hoffmann-La Roche Ltd: FDA approves Roche's Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)

Approval based on interim RAINBOWFISH data which show pre-symptomatic babies treated with Evrysdi for at least one year were able to sit, stand and walk Prescribing information updated with FIREFISH data

FDA approves Roche's Evrysdi for use in babies under two months with spinal muscular atrophy (SMA) - Vimarsana News

FDA approves Roche's Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)

Approval based on interim RAINBOWFISH data which show pre-symptomatic babies treated with Evrysdi for at least one year were able to sit, stand and walk Prescribing information updated with FIREFISH... | May 31, 2022

Evaluation of multiple micronutrient supplementation and medium-quantity lipid-based nutrient supplementation in pregnancy on child development in rural Niger: A secondary analysis of a cluster randomized controlled trial - Vimarsana News

Evaluation of multiple micronutrient supplementation and medium-quantity lipid-based nutrient supplementation in pregnancy on child development in rural Niger: A secondary analysis of a cluster randomized controlled trial

Christopher R. Sudfeld and colleagues evaluate the benefit of multiple micronutrient supplementation and medium‐quantity lipid‐based nutrient supplementation in pregnancy on child development in rural Niger.

Source: plos.org
New three-year data for Roche's Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA) - Vimarsana News

New three-year data for Roche's Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)

91% of infants treated with Evrysdi in the FIREFISH study were still alive at three years Infants treated with Evrysdi maintained or continued to improve in measures of motor function, including their...

Neonatal Hypoglycemia Doesn't Affect Childhood Academics - Vimarsana News

Neonatal Hypoglycemia Doesn't Affect Childhood Academics

Previous studies have shown an increased risk of poor executive and visual-motor function in children with neonatal hypoglycemia.